NanoViricides unaffected by US tariff turmoil, says CFO
NanoViricides (NYSE-A:NNVC) chief financial officer Meeta Vyas talked with Proactive about the company's progress developing broad-spectrum antiviral therapeutics and how its technology remains unaffected by global market turmoil. Vyas explained that NanoViricides, based in Shelton, Connecticut, conducts all its research and development in-house, making it immune to international tariff changes.
NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative
The US Department of Agriculture (USDA) will invest up to $100 million to combat highly pathogenic avian influenza (HPAI), funding research into prevention, therapeutics, and vaccine candidates, the agency said last week. The program will prioritize novel treatments and improved diagnostics for poultry, along with vaccine development.
NanoViricides says business unaffected by US tariffs, highlights antiviral pipeline
NanoViricides (NYSE-A:NNVC) said on Tuesday that its business remains unaffected by US government tariffs, retaliatory trade policies, or federal spending cuts. In a statement, the clinical-stage biotech firm highlighted to shareholders that it develops antiviral treatments, not vaccines, and sees growing demand for broad-spectrum antiviral drugs under the policy direction of US Health and Human Services Secretary Robert Kennedy.
NanoViricides' NV-387 could provide a crucial missing weapon in the fight against US measles outbreak
NanoViricides (NYSE-A:NNVC) believes its broad-spectrum antiviral NV-387 could provide a crucial weapon piece in the fight against the ongoing measles outbreak in the US. The company responded to a recent opinion piece by Health and Human Services Secretary Robert F.
NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials
NanoViricides (NYSE-A:NNVC) is positioning itself for a pivotal year in 2025, with plans to advance its lead antiviral candidate, NV-387, into multiple Phase II clinical trials. The company is planning to accelerate its development pipeline, focusing on MPox treatment in Central Africa, viral acute respiratory infections, and a potential pediatric RSV indication.
NanoViricides announces readiness to combat bird flu with antiviral drug NV-387
NanoViricides (NYSE-A:NNVC) stated today that it is prepared to address the escalating threat of bird flu with its broad-spectrum antiviral drug, NV-387. The company asserts that NV-387 is designed to remain effective against the H5N1 virus, even as the virus undergoes rapid mutations.
NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387
With its broad-spectrum antiviral drug NV-387, NanoViricides (NYSE-A:NNVC) sees a future where patients with a range of viral diseases can access treatment as quickly as they can secure antibiotics for a bacterial infection. “Today if a patient goes to the doctor with a viral infection, they are told to go home and relax.
NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts
Bird flu is likely widespread among birds in Massachusetts, State health and environmental officials said this week on Wednesday, as new cases are reported in both wild and domestic birds across multiple municipalities. Bird flu, or H5N1, is a type of highly pathogenic avian influenza that causes severe disease in birds and occasionally infects humans.
NanoViricides taps clinical research organization for Phase II trial of NV-387
NanoViricides (NYSE-A:NNVC) said on Monday it had engaged a clinical research organization to conduct a Phase II trial for its broad-spectrum antiviral drug NV-387. The Connecticut-based company is targeting NV-387 for the treatment of MPox, a disease caused by the human Mpox virus (hMPXV), which has spurred a regional pandemic in parts of Africa, including the Democratic Republic of Congo and Uganda.
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that it is presenting at Biotech Showcase™ 2025 in San Fransisco, being held in parallel to the JP Morgan Life Sciences Conference. Event Information: Event NanoViricides Presentation at the Biotech Showcase, San Fransisco Day & Date Tuesday, January 14, 2025 Time, Track & Room 2:30pm PT, Yosemite A (Ballroom Level) Location Hilton San Fransisco - Union Square Anil R.
NanoViricides CEO discusses NV-387's broad spectrum promise - ICYMI
NanoViricides (NYSE-A:NNVC) CEO Dr Anil Diwan joined Proactive to highlight the company's lead drug candidate NV-387, which is targeting multiple viral families by mimicking receptors essential for viral infections. He highlighted that NV-387 has shown exceptional efficacy in preclinical studies, including curing RSV infections in animal models.
NanoViricides highlights urgent need for broad-spectrum antiviral solutions amid viral threats
NanoViricides (NYSE-A:NNVC) has highlighted the growing need for innovative antiviral solutions amid rising concerns over multiple viral threats, including H5N1 bird flu, COVID-19, RSV, and human metapneumovirus (hMPV). The company is advancing NV-387, a promising broad-spectrum antiviral candidate designed to target a wide range of rapidly mutating RNA viruses.
